Microencapsulated sodium butyrate reduces the frequency of abdominal pain in patients with irritable bowel syndrome

Aim Abdominal pain, defaecation disorder and change of bowel habit are the commonest symptoms of irritable bowel syndrome (IBS). The effect of microencapsulated sodium butyrate (MSB) was assessed on the severity of symptoms in patients with IBS. Method Sixty‐six patients treated with one of the st...

Full description

Saved in:

Bibliographic Details
Published in:	Colorectal disease Vol. 15; no. 2; pp. 204 - 209
Main Authors:	Banasiewicz, T., Krokowicz, Ł., Stojcev, Z., Kaczmarek, B. F., Kaczmarek, E., Maik, J., Marciniak, R., Krokowicz, P., Walkowiak, J., Drews, M.
Format:	Journal Article
Language:	English
Published:	Oxford, UK Blackwell Publishing Ltd 01-02-2013
Subjects:	abdominal pain Abdominal Pain - drug therapy Adult Butyrates - administration & dosage Capsules defaecation disorders Defecation - drug effects Double-Blind Method Drug Compounding Female Humans Irritable bowel syndrome Irritable Bowel Syndrome - drug therapy Irritable Bowel Syndrome - physiopathology Male Middle Aged Quality of Life Sodium - administration & dosage sodium butyrate Statistics, Nonparametric Surveys and Questionnaires
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Aim Abdominal pain, defaecation disorder and change of bowel habit are the commonest symptoms of irritable bowel syndrome (IBS). The effect of microencapsulated sodium butyrate (MSB) was assessed on the severity of symptoms in patients with IBS. Method Sixty‐six patients treated with one of the standard pharmacological therapies for at least 3 months were included in the study. They were randomized to receive MSB as a supplemental treatment to standard therapy or to receiving a placebo. Previous pharmacological therapy was continued throughout the study in both arms. Clinical evaluation was performed at baseline, 4 and 12 weeks. Each assessment was documented by a validated visual analogue score questionnaire measuring the severity of selected clinical symptoms, a closed‐end questionnaire measuring the frequency of selected clinical symptoms and a single closed‐end question measuring the subjective improvement of symptoms. Results After 4 weeks there was a significant decrease of pain during defaecation in the MSB group which extended to improvement of urgency and bowel habit at 12 weeks. Reduction of abdominal pain, flatulence and disordered defaecation was not statistically significant. Conclusions MSB as a supplemental therapy can reduce the frequency of selected clinical symptoms in patients with IBS, without significant influence on reducing symptom severity.
Bibliography:	istex:565EBAF0A8559A08EEEBD2DB377A57AAD8BA9C95 ArticleID:CODI3152 ark:/67375/WNG-BLZ31J21-S ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-News-1 ObjectType-Feature-3 content type line 23
ISSN:	1462-8910 1463-1318
DOI:	10.1111/j.1463-1318.2012.03152.x